RMC No. 115-2021 endorses the updated list of VAT-exempt COVID-19 vaccines and drugs under RA 11534. Businesses must apply VAT exemption immediately and maintain proper documentation.
Businesses and healthcare providers must immediately take note of the updated VAT-exempt status for certain COVID-19 medicines under Republic Act No. 11534 (Corporate Recovery and Tax Incentives for Enterprises, CREATE). Effective immediately upon endorsement, specific vaccines and treatments authorized under Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) are officially recognized as VAT-exempt. This has direct implications for sales, procurement, and accounting for VAT purposes.
What Changed
The Department of Health (DOH) formally endorsed an updated list of COVID-19 medicines that are exempt from Value Added Tax (VAT) under Section 109.1, Item (aa) of the Tax Code, as amended by RA 11534. The update includes vaccines authorized for emergency use and selected drug therapies. The specific inclusions are:
Emergency Use Authorization (EUA) Vaccines authorized by the FDA:
– COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm, Wuhan) 0.5 ml โ Suspension for injection โ 19 August 2021
– COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm, Beijing) 0.5 ml โ Suspension for injection โ 10 September 2021
Drugs authorized by the FDA under EUA:
– Casirivimab + Imdevimab (Ronapreve) 120 mg/mL โ Concentrate for Solution for Infusion โ 1 October 2021
This endorsement ensures that these medicines, when sold or procured, are excluded from VAT, relieving businesses from charging or paying the 12% VAT on these items.
Who is Affected
The updated list directly affects pharmaceutical companies, hospital and clinic procurement teams, medical distributors, and retailers of COVID-19 vaccines and therapeutics. CFOs, accountants, and tax compliance officers must update their VAT reporting systems to reflect the exemption status of these items. Government healthcare facilities and private hospitals that purchase these drugs are also affected for VAT accounting and reporting purposes.
Key Compliance Requirements
Businesses must take the following steps to comply:
1. Verify that the vaccines and drugs procured are on the DOH-endorsed updated list.
2. Ensure VAT is not charged on the sale of these VAT-exempt items.
3. Maintain proper documentation, including FDA EUA certificates and DOH endorsement letters, to substantiate VAT-exempt claims.
4. Update accounting and inventory systems to reflect VAT-exempt status for these medicines.
Deadlines and Effective Date
The endorsement was issued on 18 October 2021. Businesses should apply the VAT exemption immediately from this date forward. There is no retroactive VAT relief indicated; compliance should start with new procurement or sales occurring after the endorsement.
Penalties for Non-Compliance
Failure to correctly apply VAT exemptions may result in VAT overpayments, incorrect filings, and potential administrative penalties by the Bureau of Internal Revenue (BIR). Companies should ensure that their accounting and sales teams are aware of the exemption and have updated processes to avoid errors.
Practical Steps for Businesses
CFOs and tax practitioners should coordinate with procurement and pharmacy departments to confirm that all purchases of listed vaccines and therapeutics are documented with EUA and DOH endorsements. Ensure that invoices, sales receipts, and accounting entries reflect the VAT-exempt status. Regular review and reconciliation of VAT reports are recommended to avoid discrepancies with BIR audits.
For businesses navigating complex VAT compliance for COVID-19 products, Ablola, Saribong & Gueco offers specialized advisory services to ensure accurate reporting and adherence to BIR rules. Visit MakatiLawFirm.com for expert guidance on VAT-exempt medicines and corporate tax compliance.